← Klinické štúdie • Glomerulopatie
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V
Nábor prebieha
• Fáza 2 • intervenčná • NCT05268289
Stručný súhrn
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Základné údaje
| Ochorenia | Lupus Nephritis |
|---|---|
| Intervencie |
DRUG: Iptacopan (part 1) DRUG: Iptacopan (part 2) DRUG: Placebo + standard of care DRUG: Iptacopan + placebo |
| Sponzor | Novartis Pharmaceuticals |
| Plánovaný počet | 240 |
| Začiatok | 2022-08-10 |
| Predp. ukončenie (primárne) | 2026-03-19 |
| Krajiny | United States, Argentina, Brazil, China, Colombia, France, Germany, Hong Kong, Hungary, India, Israel, Malaysia, Mexico, Philippines, Portugal, Puerto Rico, Singapore, Spain, Turkey (Türkiye), United Kingdom |
| Posledná aktualizácia | 2026-06-01 |
Upozornenie: údaje sú orientačné a podliehajú zmenám. Úplné vstupné/vylučovacie
kritériá, kontakty a aktuálny stav nájdete v oficiálnom registri. Tento prehľad
nenahrádza lekársku konzultáciu.